Warning: The NCBI web site requires JavaScript to function. more...
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.
Cayre A, Mishellany F, Lagarde N, Penault-Llorca F.
Breast Cancer Res. 2007;9(5):R64.
Related citations
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.
Breast Cancer Res. 2007;9(5):R68.
Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.
Dandachi N, Dietze O, Hauser-Kronberger C.
Lab Invest. 2002 Aug;82(8):1007-14.
Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
Francz M, Egervari K, Kardos L, Toth J, Nemes Z, Szanto J, Szollosi Z.
J Clin Pathol. 2010 Apr;63(4):341-6. Epub 2009 Dec 3.
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R, Bartlett JM, Going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B.
J Clin Pathol. 2005 Oct;58(10):1086-90.
Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M, Morey A, Armes J, Cummings M, Francis G.
Pathology. 2006 Apr;38(2):120-4.
Validation of a fully automated HER2 staining kit in breast cancer.
Moelans CB, Kibbelaar RE, van den Heuvel MC, Castigliego D, de Weger RA, van Diest PJ.
Cell Oncol. 2010;32(1-2):149-55.
Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR, Albers EA, Weidner N.
Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):248-51.
Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.
Mod Pathol. 2002 Jun;15(6):657-65.
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Hauser-Kronberger C, Dandachi N.
J Mol Histol. 2004 Aug;35(6):647-53.
HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.
Moelans CB, de Weger RA, van Blokland MT, Ezendam C, Elshof S, Tilanus MG, van Diest PJ.
Cell Oncol. 2009;31(1):1-10.
HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL.
J Clin Pathol. 2005 Jul;58(7):710-4.
Emerging technologies for assessing HER2 amplification.
Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.
Am J Clin Pathol. 2009 Oct;132(4):539-48. Review.
HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.
Pol J Pathol. 2004;55(4):165-71.
HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
Loring P, Cummins R, O'Grady A, Kay EW.
Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):194-200.
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J.
Br J Cancer. 2003 May 19;88(10):1587-91.
Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.
Exp Mol Pathol. 2007 Jun;82(3):262-8. Epub 2007 Jan 30.
Evaluating HER2 amplification and overexpression in breast cancer.
Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG.
J Pathol. 2001 Nov;195(4):422-8.
The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M, Rasmussen BB.
Diagn Mol Pathol. 2009 Jun;18(2):96-102.
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC.
J Clin Pathol. 2007 Sep;60(9):1001-5. Epub 2006 Dec 8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on